iMAP3

Immunising mums against pertussis 3

Closed

Aim of the study

A multi-centre observational cohort study to compare the antibody responses in children whose mothers were randomised to one of two pertussis-containing vaccines in pregnancy as part of the preceding iMAP2 study or who received no pertussis-containing vaccine in pregnancy.

Inclusion and exclusion criteria

Inclusion criteria:

  • Age eligible for routine pre-school booster vaccinations (i.e., from 3 years and 4 months of age)
  • Participated in the iMAP2 trial for the group of children born to mothers who received a pertussis vaccine in pregnancy
  • Informed consent by a parent or legal guardian

Exclusion criteria:

What participating in the study involves?

Blood samples of participating children were obtained prior to and one month after the routine preschool booster vaccination. Antibody responses of the vaccine components (anti-pertussis toxin [anti-PT], anti-filamentous hemagglutinin [anti-FHA], anti-fimbriae types 2 and 3 [anti-FIM], anti-pertactin [anti-PRN], and anti-diphtheria toxoid [anti-DT], and anti-tetanus toxoid [anti-TT]) were compared between children whose mothers received one of two pertussis-containing vaccines or no pertussis-containing vaccine in pregnancy. The children were vaccinated with the routine preschool booster vaccines by the study team on the same visit as when the pre-vaccination bloods were taken.

Results about publication:

Results will be published shortly. You will find them here: link – we’ll upload them when published.